Skip to content

Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study

Shrunken Pore Syndrome's Effect on Mortality in Elective Cardiac Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04141072
Enrollment
4719
Registered
2019-10-28
Start date
2010-01-01
Completion date
2019-01-10
Last updated
2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases

Keywords

CKD, Creatinine, Cystatin C, Cardiac surgery, GFR

Brief summary

To study the impact a difference in renal clearance of small and large molecules has on long-term survival.

Detailed description

Renal dysfunction is considered a major risk factor in cardiac surgery. Renal function has earlier been estimated by creatinine and more recently by cystatin C, both of which are analysed in a blood sample. New evidence seems to suggest that if the ratio between estimated renal function from cystatin C and creatinine is below 60% the patient has a higher rate of mortality irrespective of renal function. This syndrome is named Shrunken Pore Syndrome. We study patients whom have undergone elective cardiac surgery at our institution and on whom we before the surgery has collected blood samples. They are all included in our in house patient registry and qulaity database and afterwards we match this data to our national tax registry to get data on mortality. Our aim is to evaluate whether Shrunken Pore Syndrome influence mortality following elective cardiac surgery.

Interventions

DIAGNOSTIC_TESTShrunken Pore Syndrome

eGFR Cystatin C ≤ 60% of eGFR Creatinine

Sponsors

Henrik Bjursten
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elective CABG and/or sAVR at the department of Cardiothoracic Surgery, Skåne University Hospital in Lund, Sweden between 1 January 2010 and 31 December 2015.

Exclusion criteria

* Emergency operation * Redo operation * Preoperatively missing cystatin C or creatinine

Design outcomes

Primary

MeasureTime frameDescription
Mortality during follow up1 January 2010 - 1 January 2019All cause mortality at follow up

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026